Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014:2014:648740.
doi: 10.1155/2014/648740. Epub 2014 May 12.

Shared mechanisms of neurodegeneration in Alzheimer's disease and Parkinson's disease

Anmu Xie  1 , Jing Gao  1 , Lin Xu  1 , Dongmei Meng  2
Affiliations
Review

Shared mechanisms of neurodegeneration in Alzheimer's disease and Parkinson's disease

Anmu Xie et al. Biomed Res Int. 2014.

Abstract

Alzheimer's disease (AD) and Parkinson's disease (PD) have markedly different clinical and pathological features, but these two diseases are the most common neurodegenerative disorders. Previous studies have showed that there are common mechanisms in AD and PD. Several genetic studies have revealed mutations in genes associated with the risk of AD and PD. Circumstantial evidences have shown that dysregulation of brain iron homeostasis leads to abnormal iron accumulation and results in AD as well as PD. α -Synuclein and tau take part in the mechanisms of these diseases by oxidative stress and mitochondrial dysfunction. Some studies indicated that the loss of LC noradrenergic neurons may occur early in the progression of AD and PD. Nicotinic acetylcholine receptors (nAChRs) are members of the Cys-loop superfamily of pentameric ligand-gated ion channels; some evidence showed that nicotinic receptors may be associated with AD and PD. These experimental and clinical studies may provide a scientific foundation for common shared mechanisms in AD and PD.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Shared mechanisms in AD and PD.
See this image and copyright information in PMC

References

    1. Oshiro S, Morioka MS, Kikuchi M. Dysregulation of iron metabolism in Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. Advances in Pharmacological Sciences. 2011;2011:8 pages.378278 - PMC - PubMed
    1. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS-ADRDA criteria. The Lancet Neurology. 2007;6(8):734–746. - PubMed
    1. Bondi MW, Serody AB, Chan AS, et al. Cognitive and neuropathologic correlates of Stroop Color-Word Test performance in Alzheimer’s disease. Neuropsychology. 2002;16(3):335–343. - PubMed
    1. Tolleson CM, Fang JY. Advances in the mechanisms of Parkinson's disease. Discovery Medicine. 2013;15:61–66. - PubMed
    1. Lim S-Y, Lang AE. The nonmotor symptoms of Parkinson’s disease—an overview. Movement Disorders. 2010;25(S1):S123–S130. - PubMed

MeSH terms